{"id":19313,"date":"2022-10-17T17:18:35","date_gmt":"2022-10-17T11:48:35","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19313"},"modified":"2024-06-24T10:31:36","modified_gmt":"2024-06-24T05:01:36","slug":"oncolytic-viruses-for-cancer-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment","title":{"rendered":"Oncolytic Viruses: Can Be The Next Frontier in Cancer Immunotherapy?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1873f08ba54\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1873f08ba54\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#Vectors_Used_in_Oncolytic_Virotherapy\" >Vectors Used in Oncolytic Virotherapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#Routes_for_Delivering_Oncolytic_Virus_Therapies\" >Routes for Delivering Oncolytic Virus Therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#Approved_Oncolytic_Viruses_in_Cancer_Therapy\" >Approved Oncolytic Viruses in Cancer Therapy<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#Imlygic_-talimogene_laherparepvec_T-VEC\" >Imlygic -talimogene laherparepvec (T-VEC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#DELYTACT_-teserpaturev\" >DELYTACT -teserpaturev<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#Potential_Oncolytic_Viruses_in_Cancer_Therapy_Under_Clinical_Development\" >Potential Oncolytic Viruses in Cancer Therapy Under Clinical Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#Will_DNX_2401_tasadenoturev_Pembrolizumab_Combo_be_a_Gamechanger_For_Cancer_Treatment\" >Will DNX 2401 (tasadenoturev) + Pembrolizumab Combo be a Gamechanger For Cancer Treatment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#Recent_Developments_in_Oncolytic_Viruses_for_Cancer_Therapy\" >Recent Developments in Oncolytic Viruses for Cancer Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#Future_Perspectives_of_Oncolytic_Viruses_in_Cancer_Therapy\" >Future Perspectives of Oncolytic Viruses in Cancer Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Oncolytic viruses are cancer treatments that employ a natural or reprogrammed virus capable of targeting and killing malignant cells. They are a new class of cancer agents that induce tumor regression by causing immunogenic cell death, inducing preferential replication in tumor cells, and stimulating host antitumor immunity. Oncolytic viruses are experimental cancer treatments that try to employ viruses\u2019 intrinsic features to help fight cancer. These non-human viruses proliferate primarily in cancer cells while disregarding healthy ones.<\/p>\n\n\n\n<p>Oncolytic viruses can create virions fast and genetically design new genes that boost antitumor immunity, make tumor cells more susceptible to ionizing radiation or cytotoxic treatment, and improve patient safety.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vectors_Used_in_Oncolytic_Virotherapy\"><\/span><strong>Vectors Used in Oncolytic Virotherapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Several DNA and RNA viruses may be utilized as oncolytic viruses, with DNA viruses being employed in the bulk of clinical research. Adenovirus, HSV-1, reovirus, and poxviruses were among the most frequent viruses.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"461\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24102948\/Prominently-Utilized-Vectors-in-OV-Therapy-1024x461.jpg\" alt=\"Prominently Utilized Vectors in OV Therapy\" class=\"wp-image-28446\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24102948\/Prominently-Utilized-Vectors-in-OV-Therapy-1024x461.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24102948\/Prominently-Utilized-Vectors-in-OV-Therapy-300x135.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24102948\/Prominently-Utilized-Vectors-in-OV-Therapy-150x68.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24102948\/Prominently-Utilized-Vectors-in-OV-Therapy-768x346.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24102948\/Prominently-Utilized-Vectors-in-OV-Therapy-1536x691.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24102948\/Prominently-Utilized-Vectors-in-OV-Therapy-2048x922.jpg 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24102948\/Prominently-Utilized-Vectors-in-OV-Therapy-1568x706.jpg 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Adenovirus is one of the most commonly utilized oncolytic viruses due to its immune response stimulation. Still, HSV is now being used more because it has a more extensive viral ability to carry genetic information and is more easily manipulated than adenovirus.<\/p>\n\n\n\n<p>HSV-1 is harmful to humans and can induce mucosal or skin infections and central nervous system infections, indicating the necessity for further transgene deletions and insertions to generate viable oncolytic virus therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Routes_for_Delivering_Oncolytic_Virus_Therapies\"><\/span><strong>Routes for Delivering Oncolytic Virus Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The route of administration of <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-competitive-landscape\">oncolytic viruses<\/a> are inherently tied to the kind of tumor to be treated, given that the viral pathway directly affects the success of the therapy owing to virus availability on-site and the natural barrier of the organism to fight against antigens. The distribution can be intraperitoneal, intrathecal, subcutaneous, intratumoral, and intravenous, which is connected to the treatment of distant metastases. Viruses are chosen or changed to target tumor cells, reduce pathogenicity to normal cells, reduce the antiviral immune response (to prevent viral clearance), and raise the antitumor immune response.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"456\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103021\/Routes-for-Delivering-Oncolytic-Viruses-1024x456.jpg\" alt=\"Routes for Delivering Oncolytic Viruses\" class=\"wp-image-28448\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103021\/Routes-for-Delivering-Oncolytic-Viruses-1024x456.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103021\/Routes-for-Delivering-Oncolytic-Viruses-300x134.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103021\/Routes-for-Delivering-Oncolytic-Viruses-150x67.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103021\/Routes-for-Delivering-Oncolytic-Viruses-768x342.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103021\/Routes-for-Delivering-Oncolytic-Viruses-1536x685.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103021\/Routes-for-Delivering-Oncolytic-Viruses-2048x913.jpg 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103021\/Routes-for-Delivering-Oncolytic-Viruses-1568x699.jpg 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Intratumoral administration is currently the most prevalent approach, which may limit the number and location of tumors that may be directly treated. However, prospects were interested in IV delivery in the future since it is logistically straightforward and enables the targeting of various metastatic regions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Approved_Oncolytic_Viruses_in_Cancer_Therapy\"><\/span><strong>Approved Oncolytic Viruses in Cancer Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Imlygic_-talimogene_laherparepvec_T-VEC\"><\/span><strong>Imlygic -talimogene laherparepvec (T-VEC)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Based on <strong>a Phase III OPTiM study<\/strong> that demonstrated its effectiveness against GM-CSF alone, <strong>Imlygic <\/strong>was approved in 2015 for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in <a href=\"https:\/\/www.delveinsight.com\/report-store\/melanoma-market\">patients with recurrent melanoma<\/a> after the first surgery.<\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"588\">\n\t<colgroup>\n\t\t<col width=\"232\">\n\t\t<col width=\"356\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"2\" style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">General Description: Imlygic -talimogene laherparepvec (T-VEC)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Drug Name<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Imlygic -talimogene laherparepvec (T-VEC)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Company<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Amgen<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Date of Approval<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">2015 (US and EU5)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Mechanism of action<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">GM-CSF stimulatant<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Molecule Type<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Oncolytic herpes simplex type-1 virus<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Approved Indication<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Line of therapy<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">First Line<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Cost of therapy<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">~USD 65,000<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:21px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Around the same time, <a href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-inhibitor-pipeline-insight\">PD-1 checkpoint inhibitors<\/a> were approved, which significantly increased survival periods for patients with melanoma, making it difficult for Amgen to explain its trial design with GM-CSF as the comparison arm.<\/p>\n\n\n\n<p>Another setback occurred when the findings of the OPTiM study were not very outstanding, as the medicine only delayed mOS by 4.4 months, resulting in the loss of the US FDA Fast Track designation. However, patients who had a lasting response in the first year of therapy had a 95% lower chance of mortality, which ultimately helped Amgen get approval.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>DelveInsight\u2019s Opinion: Despite being the first in class, the uptake of T-VEC has remained slow due to the limited patient pool for which it is suitable (~10% of patients who are ineligible for surgery are target candidates for Imlygic) and the limited efficacy of the drug compared to the other immunotherapies currently available for melanoma patients. Considering these limitations, we project Imlygic to, at best, generate revenue of a maximum of USD 150 million by 2032 in the 7MM.<\/em><\/strong><\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"DELYTACT_-teserpaturev\"><\/span><strong>DELYTACT -teserpaturev<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Delytact (teserpaturev) <\/strong>is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that has gained conditional and time-limited marketing authorization in Japan for <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioma-market\">malignant glioma treatment<\/a>. It is the world\u2019s first oncolytic virotherapy for <a href=\"https:\/\/www.delveinsight.com\/report-store\/brain-cancer-market\">brain cancer treatment<\/a>.&nbsp;<\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"588\">\n\t<colgroup>\n\t\t<col width=\"232\">\n\t\t<col width=\"356\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"2\" style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">General Description: DELYTACT -teserpaturev<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Drug Name<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">DELYTACT -teserpaturev<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Company<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Daiichi Sankyo<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Date of Approval<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">2021 (Japan)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Mechanism of action<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Cell death stimulants<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Molecule Type<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Third generation Oncolytic HSV-1virus<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Approved Indication<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Malignant glioma (glioblastoma)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Line of therapy<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Second Line<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Cost of therapy<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">~USD 67,529<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:21px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Data from a single-arm phase II study demonstrated that Delytact enhanced the odds of survival at one year in patients with residual or recurrent glioblastoma who had previously been treated with radiation and temozolomide chemotherapy.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>DelveInsight Opinion: DELYTACT has received conditional and time-limited marketing approval for 7 years in Japan only. Currently, it is commercially available only at hospitals that serve as trial sites, and Daiichi Sankyo will establish a stable supply system of medicine as soon as possible. Considering these limitations, we estimate that DELYTACT, at best, will generate a revenue of a maximum of USD 51 million in 2032 in the 7MM.<\/em><\/strong><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Potential_Oncolytic_Viruses_in_Cancer_Therapy_Under_Clinical_Development\"><\/span><strong>Potential Oncolytic Viruses in Cancer Therapy Under Clinical Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Approximately <strong>12 tumor<\/strong> types are currently being targeted, with a potential patient pool of <strong>1 billion<\/strong>. More than <strong>15 <\/strong>leading biotech and pharmaceutical companies in the seven major markets, including <strong>Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, <\/strong>and others are currently evaluating <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-pipeline-insight-2021\">novel oncolytic virus cancer therapies<\/a> to cater to the need of the patients.\u00a0<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"621\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103055\/Promising-Oncolytic-Virus-Therapy-in-Development-1024x621.jpg\" alt=\"Promising Oncolytic Virus Therapy in Development\" class=\"wp-image-28449\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103055\/Promising-Oncolytic-Virus-Therapy-in-Development-1024x621.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103055\/Promising-Oncolytic-Virus-Therapy-in-Development-300x182.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103055\/Promising-Oncolytic-Virus-Therapy-in-Development-150x91.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103055\/Promising-Oncolytic-Virus-Therapy-in-Development-768x466.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103055\/Promising-Oncolytic-Virus-Therapy-in-Development-1536x932.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103055\/Promising-Oncolytic-Virus-Therapy-in-Development-2048x1243.jpg 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/24103055\/Promising-Oncolytic-Virus-Therapy-in-Development-1568x951.jpg 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The pipeline for oncolytic viruses for cancer therapy is robust, with more than <strong>~ 30 assets<\/strong> in Phase II and above the stage of development. The promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-pipeline-insight-2021\">oncolytic cancer therapies in the pipeline<\/a> include <strong>ONCOS-102, RP1 (Vusolimogene Oderparepvec), GL-ONC1, CAN-2409, DNX-2401 (Tasadenoturev), PEXA-VEC (Pexastimogene Devacirepvec; JX-594), G207, LOAd703, Lerapolturev (Formerly Known as PVSRIPO), CG0070, <\/strong>and others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_DNX_2401_tasadenoturev_Pembrolizumab_Combo_be_a_Gamechanger_For_Cancer_Treatment\"><\/span><strong>Will DNX 2401 (tasadenoturev) + Pembrolizumab Combo be a Gamechanger For Cancer Treatment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>DNX-2401<\/strong> <strong>(DNAtrix)<\/strong> is an oncolytic immunotherapy developed<strong> <\/strong>to meet the twin requirements of high potency and safety. To accomplish this, two stable genetic modifications in the adenovirus genome were made such that it replicates exclusively in Rb pathway defective cells and efficiently infects tumor cells.<\/p>\n\n\n\n<p><strong>Pembrolizumab <\/strong>developed by <strong>Merck <\/strong>is a humanized monoclonal anti-programmed cell death-1 (PD-1) antibody (IgG4\/kappa isotype with a stabilizing sequence change in the Fc region) generated by recombinant DNA technology in Chinese hamster ovary cells.<\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"588\">\n\t<colgroup>\n\t\t<col width=\"232\">\n\t\t<col width=\"356\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"2\" style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">General Description: DNX 2401 (tasadenoturev) + Pembrolizumab<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Drug Name<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">DNX 2401 (tasadenoturev) + Pembrolizumab<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Company<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">DNAtrix \/Merck Sharp &amp; Dohme Corp.&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Mechanism of action<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Immunostimulants<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Molecule Type<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Oncolytic Virus<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Patient Segment<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Recurrent Glioblastoma<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase II<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:232px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Designations<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:356px\">\n\t\t\t<p style=\"line-height:1.3800000000000001; text-align:justify\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Fast Track Designation, Orphan Drug Designation (FDA), PRIME (EMA), Promising Innovative Medicine (PIM) (MHRA)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:21px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>DNAtrix<\/strong>, in collaboration with <strong>Merck Sharp &amp; Dohme Corp.<\/strong>, currently planned a <strong>Phase III trial<\/strong> for <strong>DNX-2401 plus pembrolizumab combo<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/recurrent-glioblastoma-market\">recurrent glioblastoma treatment<\/a> with the trial acronym <strong>\u201cIGNITE.\u201d<\/strong><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Analyst Comments: Overall, these findings provide the first clinical evidence that DNX-2401 can provide a direct oncolytic impact followed by an antitumor immune response. Insofar as DNX-2401 is extremely effective due to increased infectivity afforded by the RGD motif, it is capable of increasing antigen presentation; we infer that these actions contribute to immune cell infiltration and anticancer activity.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Developments_in_Oncolytic_Viruses_for_Cancer_Therapy\"><\/span><strong>Recent Developments in Oncolytic Viruses for Cancer Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>June 2022, Targovax <\/strong>announced that the US FDA approved an IND application for <strong>TG01<\/strong> combined with <strong>QS-21 STIMULON<\/strong>, which allows the preparations to initiate clinical trials in the USA to proceed.<\/li>\n\n\n\n<li>In <strong>May 2022, KaliVir Immunotherapeutics, Inc.<\/strong> announced a collaboration and global exclusive licensing agreement with Roche for the discovery, development, and commercialization of novel oncolytic vaccinia viruses derived from <strong>KaliVir\u2019s oncolytic immunotherapy VETTM platform.<\/strong><\/li>\n\n\n\n<li>In <strong>May 2022, Calidi Biotherapeutics<\/strong> had granted a new patent (No. US 11,285,194, Combination immunotherapy approach for cancer treatment) by the US Patent and Trademark Office (USPTO) related to its proprietary <strong>SuperNova (SNV) technology platform<\/strong>. The enhanced oncolytic virotherapy delivery platform was designed to provide and improve therapeutic treatments for multiple cancer indications. Calidi\u2019s product candidates are in the early stages of development and have not yet been approved by the US FDA.<\/li>\n\n\n\n<li>In <strong>March 2022, Synthetic Biologics, Inc. <\/strong>announced that it had completed the acquisition of <strong>VCN Biosciences, S.L. (VCN)<\/strong>, following the satisfaction of all closing conditions.<\/li>\n\n\n\n<li>In <strong>January 2022, Transgene and PersonGen BioTherapeutics<\/strong> announced a strategic collaboration to evaluate the feasibility and efficacy of combination therapy associating <strong>PersonGen\u2019s TAA06 CAR-T cell injection<\/strong> with intravenous (IV) administration of an armed oncolytic virus from <strong>Transgene\u2019s Invir.IO\u2122 platform<\/strong>, in solid tumors including pancreatic cancer and brain glioma. The collaboration aimed to demonstrate the combination\u2019s likely synergistic mechanisms to potentiate CAR-T cell therapy. Under the terms of the collaboration agreement, Transgene to develop multiple new oncolytic virus candidates, using its patented oncolytic virus backbone <strong>VVcopTK-RR-<\/strong> and its <strong>Invir.IO\u2122 technology platform<\/strong>, specifically for IV administration in combination with <strong>PersonGen\u2019s TAA06 CAR-T injection<\/strong>. PersonGen to evaluate the efficacy of the combination to eliminate solid tumors in preclinical models.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/20142020\/Milestone-of-Oncolytic-Virus-Therapy-Development-1024x576.jpg\" alt=\"Milestone of Oncolytic Virus Therapy Development\" class=\"wp-image-28419\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/20142020\/Milestone-of-Oncolytic-Virus-Therapy-Development-1024x576.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/20142020\/Milestone-of-Oncolytic-Virus-Therapy-Development-300x169.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/20142020\/Milestone-of-Oncolytic-Virus-Therapy-Development-150x84.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/20142020\/Milestone-of-Oncolytic-Virus-Therapy-Development-768x432.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/20142020\/Milestone-of-Oncolytic-Virus-Therapy-Development-1536x864.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/20142020\/Milestone-of-Oncolytic-Virus-Therapy-Development-2048x1152.jpg 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/20142020\/Milestone-of-Oncolytic-Virus-Therapy-Development-1568x882.jpg 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Perspectives_of_Oncolytic_Viruses_in_Cancer_Therapy\"><\/span><strong>Future Perspectives of Oncolytic Viruses in Cancer Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The approval of multiple drugs targeting various <a href=\"https:\/\/www.delveinsight.com\/blog\/oncology\">cancer indications<\/a> is predicted to change the dynamics of the oncolytic cancer therapies market in the future years.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>According to DelveInsight analysis, the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-market\"><strong>oncolytic cancer therapies market size<\/strong><\/a><strong> in the 7MM was approximately USD 122 million in 2021, which is further expected to increase at a CAGR of 32.9% by 2032. As per our estimates, the United States will have the largest oncolytic virus therapies market share.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<p>Furthermore, oncolytic viruses offer several benefits over conventional tumor immunotherapies, such as high killing effectiveness, precision targeting, fewer side effects or drug resistance, and low cost, which is propelling the oncolytic virus therapies market growth. Moreover, as some oncolytic viruses, such as Adeno oncolytic viruses, exhibit antitumor memory, they might be employed as a cancer vaccine.<\/p>\n\n\n\n<p>In addition, there is an opportunity for blockbuster drugs like <strong>Keytruda\/Opdivo <\/strong>and other IOs to target a huge <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/current-treatment-challenges-of-io-refractory-patients\">patient pool of checkpoint-resistant patients<\/a> (50-60% of their present patient pool becomes refractory).<\/p>\n\n\n\n<p>Moreover, considerable novel techniques, such as the utilization of nanoparticles, complex viral particle ligands, liposomes, polymeric particles, and immunomodulatory drugs, have been developed to investigate effective oncolytic virus delivery methods.<\/p>\n\n\n\n<p>Furthermore, existing knowledge and experience with immunotherapy create a compelling argument for institutional <a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-market\">approval of oncolytic virus cancer therapies<\/a>. Immunotherapy is being used in roughly <strong>30<\/strong> different cancer types, which will provide a large patient pool for novel emerging therapies in the coming years.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/oncolytic-virus-cancer-therapy-market\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17170922\/Oncolytic-Virus-Cancer-Therapy-Market-assessment-1024x256.png\" alt=\"Oncolytic Virus Cancer Therapy Market Assessment\" class=\"wp-image-19337\" style=\"width:1024px;height:256px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17170922\/Oncolytic-Virus-Cancer-Therapy-Market-assessment-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17170922\/Oncolytic-Virus-Cancer-Therapy-Market-assessment-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17170922\/Oncolytic-Virus-Cancer-Therapy-Market-assessment-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17170922\/Oncolytic-Virus-Cancer-Therapy-Market-assessment-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17170922\/Oncolytic-Virus-Cancer-Therapy-Market-assessment-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17170922\/Oncolytic-Virus-Cancer-Therapy-Market-assessment-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17170922\/Oncolytic-Virus-Cancer-Therapy-Market-assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1665995965117\"><strong class=\"schema-faq-question\"><strong>1. What is oncolytic virus therapy?<\/strong><\/strong> <p class=\"schema-faq-answer\">Oncolytic viruses (OVs) are a type of anti-cancer agent that promotes tumor regression by preferentially replicating in tumor cells, inducing immunogenic cell death, and stimulating antitumor immunity in the host. It employs both native and reprogrammed viruses to target and destroys cancerous cells.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665995995584\"><strong class=\"schema-faq-question\"><strong>2. How does oncolytic virus therapy work?<\/strong><\/strong> <p class=\"schema-faq-answer\">Oncolytic viruses are a new class of cancer agents that induce tumor regression by causing immunogenic cell death, inducing preferential replication in tumor cells, and stimulating host antitumor immunity. Oncolytic viruses are experimental cancer treatments that try to employ viruses\u2019 intrinsic features to help fight cancer. These non-human viruses proliferate primarily in cancer cells while disregarding healthy ones.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665996028223\"><strong class=\"schema-faq-question\"><strong>3. Are there any oncolytic viruses cancer therapy available in the market?<\/strong><\/strong> <p class=\"schema-faq-answer\">There are only two oncolytic virus cancer therapies available in the market, namely, IMLYGIC (Talimogene laherparepvec) (Amgen) and Delytact (Auidyw) (Daiichi Sankyo).\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665996046699\"><strong class=\"schema-faq-question\"><strong>4. How many companies are working on oncolytic viruses for cancer treatment?<\/strong><\/strong> <p class=\"schema-faq-answer\">More than 15 leading biotech and pharmaceutical companies, including Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others are currently evaluating novel oncolytic virus cancer therapies to cater to the need of the patients.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1665996056712\"><strong class=\"schema-faq-question\"><strong>5. Which are the oncolytic virus therapies in the pipeline?<\/strong><\/strong> <p class=\"schema-faq-answer\">The promising oncolytic cancer therapies in the pipeline include ONCOS-102, RP1 (Vusolimogene Oderparepvec), GL-ONC1, CAN-2409, DNX-2401 (Tasadenoturev), PEXA-VEC (Pexastimogene Devacirepvec; JX-594), G207, LOAd703, Lerapolturev (Formerly Known as PVSRIPO), CG0070, and others.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oncolytic viruses are cancer treatments that employ a natural or reprogrammed virus capable of targeting and killing malignant cells. They are a new class of cancer agents that induce tumor regression by causing immunogenic cell death, inducing preferential replication in tumor cells, and stimulating host antitumor immunity. Oncolytic viruses are experimental cancer treatments that try [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":19314,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[906,140,927,1787,315,394,19829,19828,1977],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-19313","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-cancer-therapies","tag-cancer-therapy","tag-cancer-treatment","tag-glioblastoma","tag-immunotherapy","tag-melanoma","tag-oncolytic-immunotherapy","tag-oncolytic-virus-therapies","tag-oncolytic-viruses","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Oncolytic Viruses: A Novel Approach to Cancer Immunotherapy<\/title>\n<meta name=\"description\" content=\"More than 15 companies are conducting various trials for oncolytic viruses, among which ~ 30 assets in mid and late stage of development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncolytic Viruses: A Novel Approach to Cancer Immunotherapy\" \/>\n<meta property=\"og:description\" content=\"More than 15 companies are conducting various trials for oncolytic viruses, among which ~ 30 assets in mid and late stage of development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-17T11:48:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-24T05:01:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17141455\/oncolytic-viruses-for-cancer-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oncolytic Viruses: A Novel Approach to Cancer Immunotherapy","description":"More than 15 companies are conducting various trials for oncolytic viruses, among which ~ 30 assets in mid and late stage of development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment","og_locale":"en_US","og_type":"article","og_title":"Oncolytic Viruses: A Novel Approach to Cancer Immunotherapy","og_description":"More than 15 companies are conducting various trials for oncolytic viruses, among which ~ 30 assets in mid and late stage of development.","og_url":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-10-17T11:48:35+00:00","article_modified_time":"2024-06-24T05:01:36+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17141455\/oncolytic-viruses-for-cancer-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment","url":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment","name":"Oncolytic Viruses: A Novel Approach to Cancer Immunotherapy","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17141455\/oncolytic-viruses-for-cancer-treatment.png","datePublished":"2022-10-17T11:48:35+00:00","dateModified":"2024-06-24T05:01:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"More than 15 companies are conducting various trials for oncolytic viruses, among which ~ 30 assets in mid and late stage of development.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665995965117"},{"@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665995995584"},{"@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996028223"},{"@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996046699"},{"@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996056712"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17141455\/oncolytic-viruses-for-cancer-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17141455\/oncolytic-viruses-for-cancer-treatment.png","width":772,"height":482,"caption":"oncolytic-viruses-for-cancer-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665995965117","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665995965117","name":"1. What is oncolytic virus therapy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Oncolytic viruses (OVs) are a type of anti-cancer agent that promotes tumor regression by preferentially replicating in tumor cells, inducing immunogenic cell death, and stimulating antitumor immunity in the host. It employs both native and reprogrammed viruses to target and destroys cancerous cells.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665995995584","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665995995584","name":"2. How does oncolytic virus therapy work?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Oncolytic viruses are a new class of cancer agents that induce tumor regression by causing immunogenic cell death, inducing preferential replication in tumor cells, and stimulating host antitumor immunity. Oncolytic viruses are experimental cancer treatments that try to employ viruses\u2019 intrinsic features to help fight cancer. These non-human viruses proliferate primarily in cancer cells while disregarding healthy ones.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996028223","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996028223","name":"3. Are there any oncolytic viruses cancer therapy available in the market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"There are only two oncolytic virus cancer therapies available in the market, namely, IMLYGIC (Talimogene laherparepvec) (Amgen) and Delytact (Auidyw) (Daiichi Sankyo).\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996046699","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996046699","name":"4. How many companies are working on oncolytic viruses for cancer treatment?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"More than 15 leading biotech and pharmaceutical companies, including Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others are currently evaluating novel oncolytic virus cancer therapies to cater to the need of the patients.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996056712","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/oncolytic-viruses-for-cancer-treatment#faq-question-1665996056712","name":"5. Which are the oncolytic virus therapies in the pipeline?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The promising oncolytic cancer therapies in the pipeline include ONCOS-102, RP1 (Vusolimogene Oderparepvec), GL-ONC1, CAN-2409, DNX-2401 (Tasadenoturev), PEXA-VEC (Pexastimogene Devacirepvec; JX-594), G207, LOAd703, Lerapolturev (Formerly Known as PVSRIPO), CG0070, and others.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/17141455\/oncolytic-viruses-for-cancer-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">cancer therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">glioblastoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Immunotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">melanoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">oncolytic immunotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">oncolytic virus therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oncolytic viruses<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer therapies<\/span>","<span class=\"advgb-post-tax-term\">cancer therapy<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">glioblastoma<\/span>","<span class=\"advgb-post-tax-term\">Immunotherapy<\/span>","<span class=\"advgb-post-tax-term\">melanoma<\/span>","<span class=\"advgb-post-tax-term\">oncolytic immunotherapy<\/span>","<span class=\"advgb-post-tax-term\">oncolytic virus therapies<\/span>","<span class=\"advgb-post-tax-term\">Oncolytic viruses<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Oct 17, 2022","modified":"Updated on Jun 24, 2024"},"absolute_dates_time":{"created":"Posted on Oct 17, 2022 5:18 pm","modified":"Updated on Jun 24, 2024 10:31 am"},"featured_img_caption":"oncolytic-viruses-for-cancer-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19313"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19313\/revisions"}],"predecessor-version":[{"id":28450,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19313\/revisions\/28450"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19314"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19313"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19313"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}